SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-362970
Filing Date
2021-12-21
Accepted
2021-12-21 06:07:54
Documents
13
Period of Report
2021-12-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d261429d8k.htm   iXBRL 8-K 28785
2 EX-99.1 d261429dex991.htm EX-99.1 11446
  Complete submission text file 0001193125-21-362970.txt   173202

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20211216.xsd EX-101.SCH 2913
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20211216_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20211216_pre.xml EX-101.PRE 11874
7 EXTRACTED XBRL INSTANCE DOCUMENT d261429d8k_htm.xml XML 3471
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 211506780
SIC: 2836 Biological Products, (No Diagnostic Substances)